PTK2 and melanoma: The high selectivity of the FAT domain targeting allows for UA-1907 and myristoylated analog UA-2012 to be a viable candidate for not only melanoma but other FAK-mediated diseases (pulmonary fibrosis, cirrhosis, pancreatic cancer, etc.).